Literature DB >> 10233877

Cirrhosis of the liver in long-term marrow transplant survivors.

S I Strasser1, K M Sullivan, D Myerson, C L Spurgeon, B Storer, H G Schoch, C S Murakami, G B McDonald.   

Abstract

Patients who survive hematopoietic cell transplantation (HCT) have multiple risk factors for chronic liver disease, including hepatitis virus infection, iron overload, and chronic graft-versus-host disease (GVHD). We studied 3,721 patients who had survived 1 or more years after HCT at a single center and identified patients with histologic or clinical evidence of cirrhosis. Risk factors for the development of cirrhosis were evaluated and compared with a group of matched control subjects. Cirrhosis was identified in 31 of 3,721 patients surviving 1 or more years after HCT, 23 of 1,850 patients surviving 5 or more years, and in 19 of 860 patients surviving 10 or more years. Cumulative incidence after 10 years was estimated to be 0.6% and after 20 years was 3.8%. The median time from HCT to the diagnosis of cirrhosis was 10.1 years (range, 1.2 to 24.9 years). Twenty-three patients presented with complications of portal hypertension, and 1 presented with hepatocellular carcinoma. Thirteen patients have died from complications of liver disease, and 2 died of other causes. Three patients have undergone orthotopic liver transplantation. Hepatitis C virus infection was present in 25 of 31 (81%) of patients with cirrhosis and in 14 of 31 (45%) of controls (P =.01). Cirrhosis was attibutable to hepatitis C infection in 15 of 16 patients presenting more than 10 years after HCT. There was no difference in the prevalence of acute or chronic GVHD, duration of posttransplant immunosuppression, or posttransplant marrow iron stores between cases and controls. Cirrhosis is an important late complication of hematopoietic cell transplantation and in most cases is due to chronic hepatitis C. Long-term survivors should be evaluated for the presence of abnormal liver function and hepatitis virus infection.

Entities:  

Mesh:

Year:  1999        PMID: 10233877

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.

Authors:  George B McDonald
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

Review 2.  Hepatitis C virus and allogeneic stem cell transplantation still matters!

Authors:  Gérard Socié; Régis Peffault de Latour; George B McDonald
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

3.  Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents.

Authors:  Andreas Kyvernitakis; Parag Mahale; Uday R Popat; Ying Jiang; Jeff Hosry; Richard E Champlin; Harrys A Torres
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-19       Impact factor: 5.742

4.  National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Authors:  Michael L Nieder; George B McDonald; Aiko Kida; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Michael A Pulsipher; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-01       Impact factor: 5.742

Review 5.  Surviving childhood cancer: the impact on life.

Authors:  Robert E Goldsby; Denah R Taggart; Arthur R Ablin
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

7.  Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Carlos A Ramos; Rima M Saliba; Leandro de Pádua; Ola Khorshid; Elizabeth J Shpall; Sergio Giralt; Poliana A Patah; Chitra M Hosing; Uday R Popat; Gabriela Rondon; Issa F Khouri; Yago L Nieto; Richard E Champlin; Marcos de Lima
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

8.  Natural course of HCV infection in childhood cancer survivors.

Authors:  Francesca Fioredda; Andrea Moser; Luisella Bertoluzzo; Herwig Lackner; Raffaella Giacchino; Milena La Spina; Luisella Lazier; Caterina Riva; Mareva Giacchino; Donatella Fraschini; Eva Frey; Angela Sementa; Angela Pistorio; Riccardo Haupt
Journal:  Support Care Cancer       Date:  2009-10-27       Impact factor: 3.603

Review 9.  Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.

Authors:  Eric J Chow; Lynnette Anderson; K Scott Baker; Smita Bhatia; Gregory M T Guilcher; Jennifer T Huang; Wendy Pelletier; Joanna L Perkins; Linda S Rivard; Tal Schechter; Ami J Shah; Karla D Wilson; Kenneth Wong; Satkiran S Grewal; Saro H Armenian; Lillian R Meacham; Daniel A Mulrooney; Sharon M Castellino
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-21       Impact factor: 5.742

10.  Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).

Authors:  Uwe Platzbecker; Martin Bornhäuser; Ulrich Germing; Julian Stumpf; Bart L Scott; Nicolaus Kröger; Rainer Schwerdtfeger; Alexandra Böhm; Guido Kobbe; Catrin Theuser; Werner Rabitsch; Peter Valent; Mohamed L Sorror; Gerhard Ehninger; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.